Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04984707 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
A Phase 1 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04984707 is a Phase 1 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 40 participants.
The verdict
NCT04984707, a Phase 1 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration
Interventions
- OTHER Placebo
- DRUG KX0826
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04984707
The ClinicalTrials.gov registry entry for NCT04984707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04984707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04984707 about?
NCT04984707 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration". The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration
What is the current status of trial NCT04984707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-01-28. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT04984707?
The interventions under investigation include: Placebo (OTHER), KX0826 (DRUG).
Who is sponsoring clinical trial NCT04984707?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.